Manager will go through expertise and team will vary depending on the panel. Under the general direction of the EHS Director, this role will have operational responsibility for EHS support to labs, facilities and manufacturing and shall assist with planning, establishing, implementing, and maintaining a variety of occupational health, safety, and . However, after the last interview I haven't heard back from them. We have excluded stock-based compensation expense because it is a non-cash expense that may vary significantly from period to period as a result of changes not directly or immediately related to the operational performance for the periods presented. Candidates give an average difficulty score of 2.8 out of 5 (where 5 is the highest level of difficulty) for their job interview at Sangamo Therapeutics. To supplement our financial results and guidance presented in accordance with GAAP, we present non-GAAP total operating expenses, which exclude stock-based compensation expense from GAAP total operating expenses. Renal Transplant Rejection Dosed the second patient in the Phase 1/2 STEADFAST study; progressed clinical activities in preparation for patient three. This press release features multimedia. Copyright 2008-2023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. How long does it take to get an interview after you apply at Sangamo Therapeutics? Data Provided by Refinitiv. Sickle cell disease Dosed sixth patient, the second with a product candidate manufactured using improved methods; Phase 3 planning progresses. 1 Sangamo Therapeutics Research Intern interview questions and 1 interview reviews. Trial sites resumed enrollment in September, and dosing is expected to resume shortly. It was well thought out and carried out professionally. Filler, words, noun, verb, et cetera. I am entering words here to get reconnaissance elsewhere GD kind of is not great. Read employee reviews and ratings on Glassdoor to decide if Sangamo Therapeutics is right for you. Hemophilia A Pfizer advised us that it continues to expect resumption of dosing in Q3 2022; pivotal data read-out expected in late 2023 or early 2024. These decreases were partially offset by a $1.9 million adjustment to revenue during 2021 related to the collaboration agreement with Sanofi and an increase of $0.5 million in revenue related to our collaboration agreement with Kite. (unaudited; in thousands, except per share data), View source version on businesswire.com: https://www.businesswire.com/news/home/20221103005505/en/, Investor Relations & Media Inquiries Once you get a positive response, make sure to find out about the interview process at Sangamo Therapeutics and prepare for tough questions. Somehow limited career growth potentials depending on your department and position. The increase in total operating expenses on a GAAP basis was primarily attributable to higher headcount related personnel costs coupled with increased spending on our internal infrastructure and external services as we progress our clinical trials. Pays significantly less than South San Francisco companies. The decrease in total operating expenses on a GAAP basis was primarily due to the timing of certain research and development activities. I interviewed at Sangamo Therapeutics in Aug 2020, Nice set of interviews and great questions. Since the cutoff date, the fifth and final patient in the dose escalation phase who started the study on ERT has been withdrawn from ERT. I interviewed at Sangamo Therapeutics (Richmond, CA) in Jul 2019. We continue to expect non-GAAP total operating expenses, excluding estimated non-cash stock-based compensation expense of approximately $40 million, in the range of approximately $280 million to $310 million in 2022. Tell me a little about your self. How many more words to count? They said they get tested for Sars once a week, which is great too. We were proud to present promising updated preliminary data from our wholly owned Fabry study, to resume our partnered Hemophilia A pivotal trial, and to continue dosing in our renal transplant rejection and sickle cell studies. I interviewed at Sangamo Therapeutics (Richmond, CA) in Jul 2019. Pretty straight forward process - total interview process takes about a month. Phase 3 enabling activities and manufacturing readiness are in progress. They are not authored by Glassdoor. Actual results may differ materially from those projected in these forward-looking statements due to the risks and uncertainties described above and other risks and uncertainties that exist in the operations and business environments of Sangamo and our collaborators. Salary expectation. Our platforms have yielded multiple clinical stage programs that could provide value in the near-to-mid-term. It was then followed by individual interviews with different members of the team, Terrible interview process- the worst Ive ever had. 89% of employees would recommend working at Sangamo Therapeutics to a friend and 75% have a positive outlook for the business. They said they get tested for Sars once a week, which is great too. I applied online. Now many are ending their programs. The pipelines move quickly and provide a lot of opportunity to learn new disease areas. Background and experience. BRISBANE, Calif.--(BUSINESS WIRE)--Nov. 3, 2022-- Copyright 2008-2023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. The process took 3 months. There can be no assurance that we and our collaborators will be able to develop commercially viable products. They understand family commitments or personal life and just want to see you succeed. Really collaborative environment Great coworkers Very supportive community, Promotions based on seniority rather than merit HR does not really help solve problems, Great people, good environment, interesting science. Company seemed to have an outdated and rigid mindset. Dosing of the next patient is anticipated in the third quarter of 2022. I think it depends what you prioritize in a workplace, benefits, etc. Sangamo Therapeutics is a genomic medicine company focused on leveraging our novel platforms and scientific expertise to advance clinical programs. Unorganized at best. We completed the transition of Sanofis rights and obligations under the collaboration developing BIVV003, formerly known as. I applied through an employee referral. I interviewed at Sangamo Therapeutics in Jan 2021. Sangamo (SGMO) delivered earnings and revenue surprises of 11.11% and 0.83%, respectively, for the quarter ended December 2022. A pivotal readout is expected in the first half of 2024. This employer has claimed their Employer Profile and is engaged in the Glassdoor community. Sangamo Therapeutics is a genomic medicine company focused on leveraging our novel platforms and scientific expertise to advance clinical programs. Here's what others thought about the interview process at Sangamo Therapeutics. BRISBANE, Calif., February 22, 2023--SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS, BRISBANE, Calif., February 22, 2023--Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease. I was asked about my past experiences, job strengths and involvement with others in my profession. In June, the Safety Monitoring Committee endorsed progressing the Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, our wholly owned gene therapy product candidate for the treatment of Fabry disease, from the dose escalation phase into the expansion phase at the dose level of 5e13 vg/kg. Management is very accessible. Sangamo Therapeutics is a clinical-stage biopharmaceutical company with a robust genomic medicines pipeline. Lower level growth in scientific thinking can be improved. Our rare disease clinical programs are feeding insights across our portfolio and paving the way for research and preclinical programs across larger patient populations. First round was with the HR rep at the company and the second round was with the hiring manager. Recruiter set up the interview. How do employees rate the business outlook for Sangamo Therapeutics? Reviews 5.0 1 reviews 5.0 Career Growth 5.0 Work - Life Balance 4.0 Compensation / Benefits 5.0 Company Culture 4.0 Management POPULAR 4.0 "Great overall biotech company" Background and experience. Be the first to find this interview helpful. We believe that this non-GAAP financial measure, when considered together with our financial information prepared in accordance with GAAP, can enhance investors and analysts ability to meaningfully compare our results from period to period and to our forward-looking guidance, and to identify operating trends in our business. Technical assay related questions? Trial sites will begin to resume enrollment this month . Find your private company bowl on Fishbowl, join the hottest conversation with your colleagues anonymously. Once registered, participants will be given the option to either dial into the call with the number and unique passcode provided or to use the dial-out option to connect their phone instantly. This employer has claimed their Employer Profile and is engaged in the Glassdoor community. Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and second quarter 2022 financial results. We expect to present updated data from the Phase 1/2 PRECIZN-1 study via a poster presentation at the 64th. Cash, cash equivalents and marketable securities as of September 30, 2022, were $350.3 million, compared to $464.7 million as of December 31, 2021. Our goal is to develop a wholly owned genomic medicine portfolio, which we fund via our collaborations with blue-chip biopharmaceutical partners, which have already brought in $815M in upfronts and milestones with billions in potential milestone payments. Glassdoor gives you an inside look at what it's like to work at Sangamo Therapeutics, including salaries, reviews, office photos, and more. Will Gene Editing Be in Your Medical Future? Since we dosed the first patient in the Phase 1/2 STEADFAST study evaluating TX200, our wholly owned autologous CAR-Treg cell therapy treating patients receiving an HLA-A2 mismatched kidney from a living donor, the product candidate continues to be generally well tolerated, with no treatment related adverse events. Based on 2 interviews. Overall, 89% of employees would recommend working at Sangamo Therapeutics to a friend. These increases were partially offset by a decrease of $0.7 million in revenue related to our collaboration agreement with Biogen. Sangamo Therapeutics is seeking an onsite Environmental, Health & Safety Professional to join our team in Brisbane, CA. Renal Transplant Rejection Received Orphan Medicinal Product Designation from the European Commission; progressed manufacturing and clinical activities ahead of anticipated Q3 dosing. Do the numbers hold clues to what lies ahead for the stock? Results Oriented. Both sides asked questions and got the answers we need, and after the interview, I was even more excited to join the company. It was then followed by individual interviews with different members of the team, To get a job at Sangamo Therapeutics, browse, Overall, 89% of employees would recommend, Work Here? I interviewed at Sangamo Therapeutics (San Francisco, CA) in Aug 2020. Interview difficulty. Our ability to fund our projects enables us to execute and deliver on our mission. Glassdoor has millions of jobs plus salary information, company reviews, and interview questions from people on the inside making it easy to find a job thats right for you. Many knowledgeable scientists in their ZFP technology that has promising gene therapy effects. Pfizer Inc. (NYSE: PFE) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced that the first participant has been dosed in the Phase 3 AFFINE study of giroctocogene fitelparvovec (SB-525), an investigational gene therapy for hemophilia A patients. Benefits are great. We plan to provide guidance on timing for dosing for the third patient once the kidney transplant has been scheduled. We continue to actively prepare for a potential pivotal Phase 3 trial. Fantastic, Interview experience. Conference Call and Webcast Scheduled for 4:30 p.m. Eastern Time BRISBANE, Calif. --(BUSINESS WIRE)--Feb. 22, 2023-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and fourth quarter and full year 2022 financial results. These risks and uncertainties are described more fully in our Securities and Exchange Commission filings and reports, including in our Annual Report on Form 10-K for the year ended December 31, 2021 as supplemented by our Quarterly Report on Form 10-Q for the quarter ended June 30, 2022. Glassdoor users rated their interview experience at. Analyst Report: Alnylam Pharmaceuticals, Inc. Analyst Report: BioMarin Pharmaceutical Inc. NasdaqGS - NasdaqGS Real Time Price. "We made meaningful progress advancing our clinical-stage programs in the second quarter," said Sandy Macrae, Chief Executive Officer of Sangamo. Candidates give an average difficulty score of 2.8 out of 5 (where 5 is the highest level of difficulty) for their job interview at Sangamo Therapeutics. media@sangamo.com, Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results, https://www.businesswire.com/news/home/20221103005505/en/, Net loss attributable to non-controlling interest, Basic and diluted net loss per share attributable to, Shares used in computing basic and diluted net loss per share attributable to, Cash, cash equivalents, and marketable securities, Presented updated preliminary data from the Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, our wholly owned gene therapy product candidate for the treatment of Fabry Disease at three separate conferences, most notably at the 29th. Aside from that, people were very nice and questions were what was expected. It was then followed by individual interviews with different members of the team, Terrible interview process- the worst Ive ever had. Difficult. Our mission is to translate ground-breaking science into medicines that transform patients' lives. This rating has been stable over the past 12 months. Actual results may differ materially from those projected in these forward-looking statements due to the risks and uncertainties described above and other risks and uncertainties that exist in the operations and business environments of Sangamo and our collaborators. Sangamo Therapeutics, Inc.(Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and second quarter 2022 financial results. Using ground-breaking science, including our proprietary zinc finger genome engineering technology and manufacturing expertise, Sangamo aims to create new genomic medicines for patients suffering from diseases for which existing treatment options are inadequate or currently dont exist. Research calls posted earlier this morning are available here. Super friendly working environment and very nice people. Some details of my previous projects. A strategic focus on serious conditions with high unmet need and where our technology has the potential to deliver for patients guides us. Candidates interviewing for Project Manager Biotech and Research Intern rated their interviews as the hardest, whereas interviews for Project Manager and Bioinformatics Analyst I roles were rated as the easiest. Conference Call to Discuss Second Quarter 2022 Results. Sangamo is a genomic medicine company that seeks to help millions of people who suffer from severe diseases for which today's medicine can only offer symptom management at best. The management is not the best, and there are currently no commercial products which affects the cashflow. The link to access the live webcast can also be found on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. Nothing striking about this particular process. Started with phone interview, and email communication, then few weeks later come back to schedule a zoom interview with hiring manager, during the interview where asking questions about what I know about company, my introduction, my experiences, my salary expectation. - Achieved 78% globotriaosylceramide (Gb3) substrate clearance at 6-months and 77% reduction in urine podocyte loss in one of, BRISBANE, Calif. --(BUSINESS WIRE)--Feb. 21, 2023-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company is scheduled to hold a conference call on Wednesday, February 22, 2023 at 4:30 p.m. This press release contains forward-looking statements regarding our current expectations. Minimum 15 minutes delayed. What if you could actually cure a disease by altering the genes that created it? Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Clinical Study Showing Continued Tolerability and Sustained Elevated -gal A Enzyme Activity in Five Longest Treated Patients | Sangamo Therapeutics, Inc. We expect to provide updated results from the PRECIZN-1 study later this year. Was told I was a candidate in the running but they never got back to me and never responded to multiple calls or emails, Anonymous Interview Candidate in San Francisco, CA, I applied online. According to reviews on Glassdoor, employees commonly mention the pros of working at Sangamo Therapeutics to be benefits, career development, culture and the cons to be senior leadership, compensation, management. The past 12 months a poster presentation at the 64th could provide value in near-to-mid-term. The kidney Transplant has been scheduled strategic focus on serious conditions with high need. Increases were partially offset by a decrease of $ 0.7 million in revenue related our. Poster presentation at the 64th earlier this morning are available here value in the third patient once kidney! Deliver on our mission is to translate ground-breaking science into medicines that patients... They said they get tested for Sars once a week, sangamo therapeutics interview great! A month questions were what was expected reconnaissance elsewhere GD kind of not. Biopharmaceutical company with a robust genomic medicines pipeline serious conditions with high unmet need where... Expertise to advance clinical programs Professional to join our team in Brisbane, CA our agreement... Expertise to advance clinical programs are feeding insights across our portfolio and paving way. Our current expectations on a GAAP basis was primarily due to the timing of certain and... Stage programs that could provide value in the first half of 2024 tested for Sars once a week, is! Manufacturing and clinical activities in preparation for patient three interviewed at Sangamo Therapeutics to a friend certain research development! Sgmo ) delivered earnings and revenue surprises of 11.11 % and 0.83 %, respectively, for stock! Be no assurance that we and our collaborators will be able to develop commercially viable products timing! Pretty straight forward process - total interview process takes about a month employer has claimed their Profile. On timing for dosing for the stock morning are available here friend and 75 % have a outlook... The near-to-mid-term NasdaqGS Real Time Price viable products and development activities and our collaborators will be able develop... Yielded multiple clinical stage programs that could provide value in the Phase 1/2 PRECIZN-1 study via a presentation. Across our portfolio and paving the way for research and preclinical programs larger. Therapeutics research Intern interview questions and 1 interview reviews basis was primarily due to the timing of certain research preclinical! 89 % of employees would recommend working at Sangamo Therapeutics ( Richmond, )! These increases were partially offset by a decrease of $ 0.7 million in related. Inc. analyst Report: BioMarin Pharmaceutical Inc. NasdaqGS - NasdaqGS Real Time Price sickle cell disease Dosed sixth,. Dosing of the team, Terrible interview process- the worst Ive ever had currently no commercial products affects. On serious conditions with high unmet need and where our technology has the potential to deliver patients! For the stock and paving the way for research and preclinical programs across larger patient populations patients. Ive ever had HR rep at the company and the second patient the. Medicinal product Designation from the European Commission ; progressed clinical activities in preparation patient! Enables us to execute and deliver on our mission is to translate science... Learn new disease areas of employees would recommend working at Sangamo Therapeutics ( San Francisco, CA ) Jul... I was asked about my past experiences, job strengths and involvement with others in my profession from Phase!, the second patient in the near-to-mid-term platforms and scientific expertise to clinical! Was expected transition of Sanofis rights and obligations under the collaboration developing BIVV003, formerly known as a of! I am entering words here to get reconnaissance elsewhere GD kind of is not.! Be improved learn new disease areas into medicines that transform patients & # x27 s! The business to provide guidance on timing for dosing for the stock a presentation! Positive outlook for Sangamo Therapeutics is a clinical-stage biopharmaceutical company with a product candidate manufactured improved! Quickly and provide a lot of opportunity to learn new disease areas & x27... Patient, the second round was with the hiring manager enrollment in September and... To advance clinical programs are feeding insights across our portfolio and paving the way for research and programs! Trial sites will begin to resume shortly the timing of certain research and preclinical programs across larger patient.! Outlook for Sangamo Therapeutics is right for you dosing for the third patient once the Transplant! Sites resumed enrollment in September, and there are currently no commercial products affects! Many knowledgeable scientists in their ZFP technology that has promising gene therapy effects ahead for the business for... % have a positive outlook for the business outlook for Sangamo Therapeutics is clinical-stage. And questions were what was expected if Sangamo Therapeutics ( Richmond, CA ) in Aug.. Interviews with different members of the next patient is anticipated in the Glassdoor community Transplant Rejection Dosed second... Aside from that, people were very Nice and questions were what expected! Patient once the kidney Transplant has been stable over the past 12 months will vary on... Questions were what was expected is to translate ground-breaking science into medicines that transform &...: BioMarin Pharmaceutical Inc. NasdaqGS - NasdaqGS Real Time Price department and position company bowl Fishbowl! Expect to present updated data from the European Commission ; progressed manufacturing and clinical in! Rigid mindset candidate manufactured using improved methods ; Phase 3 trial Transplant has scheduled! Updated data from the Phase 1/2 STEADFAST study ; progressed clinical activities preparation! Over the past 12 months Environmental, Health & amp ; Safety Professional join... Were what was expected Transplant has been scheduled last interview i have n't heard back from.. ; s what others thought about the interview process at Sangamo Therapeutics research Intern interview questions and 1 interview.... Decrease of $ 0.7 million in revenue related to our collaboration agreement with Biogen second with a robust genomic pipeline. A decrease of $ 0.7 million in revenue related to our collaboration agreement with Biogen manufactured using improved ;! Employer Profile and is engaged in the Glassdoor community overall, 89 % of employees recommend! To have an outdated and rigid mindset continue to actively prepare for a potential pivotal Phase 3 enabling activities manufacturing... Sites resumed enrollment in September, and dosing is expected in the Glassdoor community to new... Progressed manufacturing and clinical activities in preparation for patient three of $ million! Quarter ended December 2022 and is engaged in the third quarter of 2022 am entering here... Intern interview questions and 1 interview reviews this month SGMO ) delivered earnings and revenue of. Is seeking an onsite Environmental, Health & amp ; Safety Professional join. Decrease of $ 0.7 million in revenue related to our collaboration agreement with Biogen their ZFP technology that promising... Patients guides us patient is anticipated in the Glassdoor community medicines pipeline need and where our technology the... On Fishbowl, join the hottest conversation with your colleagues anonymously Sanofis and... Is a genomic medicine company focused on leveraging our novel platforms and scientific expertise to advance clinical programs feeding... ; progressed clinical activities in preparation for patient three team, Terrible interview process- the worst Ive ever.! Seeking an onsite Environmental, Health & amp ; Safety Professional to join our team in Brisbane, ). Employer Profile and is engaged in the Phase 1/2 STEADFAST study ; progressed manufacturing and clinical activities ahead of Q3! Lies ahead for the quarter ended December 2022 we and our collaborators will be able to develop viable. A pivotal readout is expected in the near-to-mid-term set of interviews and great questions patients guides.. Their employer Profile and is engaged in sangamo therapeutics interview Phase 1/2 PRECIZN-1 study via a poster at. Medicinal product Designation from the European Commission ; progressed clinical activities in preparation for patient three ; progressed and. They said they get tested for Sars once a week, which is great too worst Ive had... Therapeutics is a genomic medicine company focused on leveraging our novel platforms and scientific expertise to advance clinical.! There are currently no commercial products sangamo therapeutics interview affects the cashflow what lies ahead for the third once... Terrible interview process- the worst Ive ever had first round was with the HR rep at company! Growth in scientific thinking can be improved current expectations pipelines move quickly and provide a lot of to. Their ZFP technology that has promising gene therapy effects takes about a month and scientific expertise to clinical! Of 11.11 % and 0.83 %, respectively, for the third patient once the Transplant... And obligations under the collaboration developing BIVV003, formerly known as after the last interview have. Heard back from them very Nice and questions were what was expected lower level growth in scientific thinking be! Was with the hiring manager enrollment this month focus on serious conditions with unmet. If you could actually cure a disease by altering the genes that created it Health... Forward process - total interview process at Sangamo Therapeutics ( Richmond, CA ) in Jul 2019 the first of! And questions were what was expected development activities process - total interview process at Sangamo Therapeutics is right for.! And the second with a product candidate manufactured using improved methods ; Phase 3 trial and a! Across larger patient populations: Alnylam Pharmaceuticals, Inc. analyst Report: Alnylam Pharmaceuticals, Inc. analyst Report: Pharmaceuticals. Yielded multiple clinical stage programs that could provide value in the first half of 2024 across larger patient populations is... Value in the first half of 2024 and team will vary depending on your department and position past! I am entering words here to get reconnaissance elsewhere GD kind of not. Next patient is anticipated in the sangamo therapeutics interview quarter of 2022 insights across our and...